Reimbursement policy in the US saw major upheaval in the second half of 2025. New mandates, stalled subsidy negotiations, and pricing pressures created major uncertainty for payers, providers, and ...

The top 5 most-read dermatology content of 2025 on AJMC.com included innovative advances from artificial intelligence ...

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life ...

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

Sustaining progress in the development of lifesaving cancer therapies will require aligning policy with science, advancing value-based care, and strengthening collaboration to ensure technologies ...

Here are the top 5 most-read CRC articles in 2025. From cutting-edge AI detection tools to rising incidence in younger adults ...

Expanding service lines in community oncology practices enhances patient experience and strengthens community ties, offering ...

AA is a chronic, immune-mediated dermatologic condition characterized by non-scarring hair loss, affecting approximately 1% to 2% of the global population. Its unpredictable course and visible ...

The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...

OneOncology supports 33 practices, providing infrastructure and expertise for advanced therapies and value-based care, while ...

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...